Trial intelligence / Profile preview

AMAGINE-2: Brodalumab vs Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis

2012-000656-34Phase 3Terminated

Sponsor
Amgen
Start
May 2012
Modality
Monoclonal Antibodies → Antibody-Based Therapeutics
Countries
1
01

Overview

A Phase 3 trial of brodalumab in plaque psoriasis, psoriasis, sponsored by Amgen. Started May 2012; status: terminated.

02

Drugs

brodalumab
03

Conditions

plaque psoriasispsoriasis

Beyond the preview

Go deeper on 2012-000656-34.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2012-000656-34.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call